Cancer cells rely on a large family of cytoplasmic and receptor tyrosine kinases to initiate tumorigenic signaling pathways that ultimately activate downstream signaling molecules, including serine/threonine kinases, which are effectors of their immunosuppressive properties. Here, MARK2 is linked to cancer.